Autolus Therapeutics plc (6A3A) - Total Liabilities

Latest as of September 2025: €396.50 Million EUR ≈ $463.54 Million USD

Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has total liabilities worth €396.50 Million EUR (≈ $463.54 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Autolus Therapeutics plc to assess how effectively this company generates cash.

Autolus Therapeutics plc - Total Liabilities Trend (2017–2024)

This chart illustrates how Autolus Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. Check Autolus Therapeutics plc (6A3A) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Autolus Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Autolus Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
Compass Therapeutics Inc. NASDAQ:CMPX	USA	$21.65 Million
Lingsen Precision Industries Ltd TW:2369	Taiwan	NT$2.37 Billion
SF Urban Properties AG SW:SFPN	Switzerland	CHF508.15 Million
Regulus Resources Inc V:REG	Canada	CA$1.04 Million
INPAQ Technology Co Ltd TWO:6284	Taiwan	NT$6.38 Billion
CMC Magnetics Corp TW:2323	Taiwan	NT$10.50 Billion
Lands’ End Inc NASDAQ:LE	USA	$621.65 Million
Semler Scientific Inc NASDAQ:SMLR	USA	$136.93 Million

Liability Composition Analysis (2017–2024)

This chart breaks down Autolus Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Autolus Therapeutics plc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	6.19	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.49	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.60	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Autolus Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Autolus Therapeutics plc (2017–2024)

The table below shows the annual total liabilities of Autolus Therapeutics plc from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	€355.40 Million ≈ $415.50 Million	+34.67%
2023-12-31	€263.91 Million ≈ $308.54 Million	+37.74%
2022-12-31	€191.60 Million ≈ $224.00 Million	+107.72%
2021-12-31	€92.24 Million ≈ $107.84 Million	+9.54%
2020-12-31	€84.20 Million ≈ $98.44 Million	+72.93%
2019-12-31	€48.69 Million ≈ $56.93 Million	+174.49%
2018-12-31	€17.74 Million ≈ $20.74 Million	+192.69%
2017-12-31	€6.06 Million ≈ $7.09 Million	--

About Autolus Therapeutics plc

F:6A3A Germany Biotechnology

Market Cap

$370.27 Million

€316.71 Million EUR

Market Cap Rank

#14351 Global

#1422 in Germany

Share Price

€1.19

Change (1 day)

-4.80%

52-Week Range

€1.03 - €2.24

All Time High

€40.10